image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.96
-2.06 %
$ 16.1 M
Market Cap
-2.29
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one IRIX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.96 USD, IRIDEX Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one IRIX stock under the base case scenario is HIDDEN Compared to the current market price of 0.96 USD, IRIDEX Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one IRIX stock under the best case scenario is HIDDEN Compared to the current market price of 0.96 USD, IRIDEX Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IRIX

image
$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.615 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
48.7 M REVENUE
-6.17%
-8.3 M OPERATING INCOME
17.04%
-8.91 M NET INCOME
6.90%
-7.28 M OPERATING CASH FLOW
-8.01%
-13 K INVESTING CASH FLOW
88.07%
2.6 M FINANCING CASH FLOW
52200.00%
11.9 M REVENUE
-6.30%
-205 K OPERATING INCOME
59.16%
-1.69 M NET INCOME
-102.16%
-1.15 M OPERATING CASH FLOW
7.19%
-11 K INVESTING CASH FLOW
-22.22%
6.04 M FINANCING CASH FLOW
2870.18%
Balance Sheet IRIDEX Corporation
image
Current Assets 23.6 M
Cash & Short-Term Investments 2.39 M
Receivables 8.39 M
Other Current Assets 12.8 M
Non-Current Assets 5.57 M
Long-Term Investments 0
PP&E 1.91 M
Other Non-Current Assets 3.67 M
8.19 %28.81 %43.87 %6.55 %12.58 %Total Assets$29.1m
Current Liabilities 16.6 M
Accounts Payable 6.98 M
Short-Term Debt 2.19 M
Other Current Liabilities 7.39 M
Non-Current Liabilities 10.5 M
Long-Term Debt 1.82 M
Other Non-Current Liabilities 8.66 M
25.83 %8.09 %27.32 %6.71 %32.04 %Total Liabilities$27.0m
EFFICIENCY
Earnings Waterfall IRIDEX Corporation
image
Revenue 48.7 M
Cost Of Revenue 29.2 M
Gross Profit 19.5 M
Operating Expenses 27.8 M
Operating Income -8.3 M
Other Expenses 608 K
Net Income -8.91 M
50m50m40m40m30m30m20m20m10m10m00(10m)(10m)49m(29m)20m(28m)(8m)(608k)(9m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
40.07% GROSS MARGIN
40.07%
-17.06% OPERATING MARGIN
-17.06%
-18.31% NET MARGIN
-18.31%
-424.89% ROE
-424.89%
-30.58% ROA
-30.58%
-56.66% ROIC
-56.66%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis IRIDEX Corporation
image
10m10m8m8m6m6m4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -8.91 M
Depreciation & Amortization 1.42 M
Capital Expenditures -13 K
Stock-Based Compensation 1.24 M
Change in Working Capital -1.37 M
Others -3.39 M
Free Cash Flow -7.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets IRIDEX Corporation
image
IRIX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership IRIDEX Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
147 K USD 5
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
IRIDEX Corporation, Inc. (IRIX) Q1 2025 Earnings Call Transcript IRIDEX Corporation, Inc. (NASDAQ:IRIX ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Trip Taylor - IR Patrick Mercer - CEO, President & Director Romeo Dizon - CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. seekingalpha.com - 1 month ago
Iridex Reports First Quarter 2025 Financial Results MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. globenewswire.com - 1 month ago
IRIDEX Changes Course IRIDEX's strategic review ended without a major asset sale, but a $10M investment from Novel Inspiration International offers growth potential and cash stability. Novel's investment values IRIDEX shares at $2.00/share, significantly higher than current trading prices, indicating a belief in the company's undervaluation. The recent LCD change in glaucoma treatment reimbursement could significantly boost IRIDEX's glaucoma business, potentially increasing the company's market valuation. seekingalpha.com - 1 month ago
Iridex to Report First Quarter 2025 Financial Results on May 13, 2025 MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. globenewswire.com - 1 month ago
IRIDEX Corporation (IRIX) Strategic Vision Conference Call (Transcript) IRIDEX Corporation (NASDAQ:IRIX ) Strategic Vision Conference Call April 16, 2025 5:00 PM ET Company Participants Trip Taylor - Investor Relations Patrick Mercer - Chief Executive Officer Will Moore - Board of Directors Conference Call Participants Aaron Warwick - Breakout Investors Jason Stankowski - Clayton Partners Mark Gomes - Pipeline Data Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. seekingalpha.com - 2 months ago
Iridex to Host Strategic Vision Call on April 16, 2025 MOUNTAIN VIEW, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will host a special call on April 16, 2025 to introduce Iridex and Novel's strategic vision for the Company following Novel's recent strategic investment in Iridex. globenewswire.com - 2 months ago
IRIDEX Corporation (IRIX) Q4 2024 Earnings Call Transcript IRIDEX Corporation (NASDAQ:IRIX ) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Trip Taylor - Investor Relations Department Patrick Mercer - Chief Executive Officer Romeo Dizon - Chief Financial Officer Conference Call Participants Operator Hello. And welcome to the Fourth Quarter 2024 IRIDEX Earnings Conference Call. seekingalpha.com - 2 months ago
Iridex Reports Fourth Quarter and Full Year 2024 Financial Results MOUNTAIN VIEW, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 28, 2024. globenewswire.com - 2 months ago
Iridex Announces Strategic Investment in the Company MOUNTAIN VIEW, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the closing of a strategic investment in the company resulting in $10 million of gross proceeds along with an option by the investor to fund up to $10 million of additional proceeds for future growth initiatives (the “Transaction”). The sole counterparty to the Transaction is Novel Inspiration International Co., Ltd. (“Novel”), an investment company founded in 2020, which had the assistance of William Moore, formerly both a board member and Chief Executive Officer of the company. globenewswire.com - 2 months ago
Iridex Comments on Recent Stock Price Volatility MOUNTAIN VIEW, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today commented on its recent stock price volatility. globenewswire.com - 3 months ago
Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025 MOUNTAIN VIEW, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the fourth quarter and full year 2024 and provide a business update after the close of trading on Thursday, March 27, 2025. globenewswire.com - 3 months ago
Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the publication of a landmark peer-reviewed study in Ophthalmology Therapy. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy (TLT) (also referred to as Transscleral Cyclophotocoagulation) in managing both primary and secondary glaucoma over five years. Conducted by Dr. Ronald de Crom and colleagues at the University Eye Clinic Maastricht, Netherlands, this research is the first to evaluate outcomes of MicroPulse TLT over such an extended period. globenewswire.com - 5 months ago
8. Profile Summary

IRIDEX Corporation IRIX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 16.1 M
Dividend Yield 0.00%
Description IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Contact 1212 Terra Bella Avenue, Mountain View, CA, 94043 https://www.iridex.com
IPO Date Feb. 16, 1996
Employees 93
Officers Ms. Leigh Salvo Head of Investor Relations Mr. Bassem BouHabib Vice President of International Sales Mr. Patrick Mercer Chief Executive Officer, President & Director Mr. Romeo R. Dizon Chief Financial Officer Mr. Scott A. Shuda J.D. Executive Chairman